Hazlett, Burt & Watson’s Gilead Sciences GILD Stock Holding History

Hazlett, Burt & Watson’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$408K	Sell	2,936 -249	-8%	-$34.9K	0.13%	167
2025 Q4	$392K	Buy	3,185 +285	+10%	+$34.6K	0.13%	157
2025 Q3	$322K	Sell	2,900 -75	-3%	-$8.53K	0.11%	166
2025 Q2	$330K	Buy	2,975 +50	+2%	+$5.32K	0.14%	145
2025 Q1	$327K	Buy	2,925 +25	+0.9%	+$2.58K	0.15%	139
2024 Q4	$269K	Hold	2,900	–	–	0.12%	164
2024 Q3	$243K	Hold	2,900	–	–	0.11%	178
2024 Q2	$199K	Hold	2,900	–	–	0.1%	182
2024 Q1	$213K	Hold	2,900	–	–	0.13%	164
2023 Q4	$234K	Hold	2,900	–	–	0.16%	136
2023 Q3	$217K	Buy	2,900 +35	+1%	+$2.69K	0.16%	137
2023 Q2	$220K	Buy	2,865 +10	+0.4%	+$798	0.16%	129
2023 Q1	$237K	Buy	2,855 +5	+0.2%	+$414	0.19%	111
2022 Q4	$245K	Sell	2,850 -200	-7%	-$15.8K	0.22%	103
2022 Q3	$188K	Hold	3,050	–	–	0.18%	116
2022 Q2	$188K	Hold	3,050	–	–	0.17%	121
2022 Q1	$181K	Buy	+3,050	New	+$195K	0.14%	147

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Hazlett, Burt & Watson's GILD Position: Q1 2026 in Review

Hazlett, Burt & Watson reduced its Gilead Sciences (GILD) stake by 7.8% in Q1 2026, selling an estimated $34.9K and leaving 2,936 shares worth $408K. The position accounts for 0.13% of the portfolio, ranked #167.

Hazlett, Burt & Watson first reported a position in GILD in Q1 2022 and has held it in 17 quarters since. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Hazlett, Burt & Watson held 2,936 shares of Gilead Sciences worth $408K as of Q1 2026.
Hazlett, Burt & Watson sold 249 Gilead Sciences shares in Q1 2026, an estimated $34.9K.
Gilead Sciences made up 0.13% of Hazlett, Burt & Watson's portfolio in Q1 2026, its #167 holding.
Hazlett, Burt & Watson first reported a position in Gilead Sciences in Q1 2022 and has held it in 17 quarters since.
2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.